Compare Natera Inc. Common Stock (NTRA) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Vanguard Total Stock Market Index Fund ETF trades at $375.7 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 40.3× Natera Inc. Common Stock's market cap, and Vanguard Total Stock Market Index Fund ETF is more actively traded (2,460,185 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Total Stock Market Index Fund ETF for 132 Days on average.
| NTRA | VTI | |
|---|---|---|
Market Cap | $57.03B | $2.30T |
Volume | 1,131,157 | 2,460,185 |
Sector | Health | — |
52-Week High | $425.64 | $384.30 |
52-Week Low | $179.42 | $311.68 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VTI trades at $381.32, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. The ETF offers broad U.S. equity exposure, though key financial ratios are not provided in the data. Recent news highlights its appeal for long-term investors seeking diversification and low-cost market access.
The outlook remains positive given strong technical momentum and media optimism, but risks include market concentration in top holdings and broader economic volatility. Investors benefit from VTI's extensive diversification, yet should monitor allocation weights and macroeconomic trends for potential impacts on returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
